Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.

ABSTRACT:

SUBMITTER: Cortes J 

PROVIDER: S-EPMC8152787 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature